4 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

3 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

4 - Fortrea Holdings Inc. (0001965040) (Issuer)

SAN DIEGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from his position as Executive Chairman of the Board and that the Board of Directors has unanimously elected R. Andrew Eckert to succeed him as Chairman of the Board, effective December 5, 2024. Carl Hull founded Maravai in 2014 and served as Chief Executive Officer, assuming the role of Executive Chairman in October 2022. "Leading Maravai has been the single most rewarding experience in my career. I am extremely proud of what we have

DURHAM, N.C., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced that Chairman and Chief Executive Officer, Tom Pike and Chief Financial Officer, Jill McConnell will present at the Citi Global Healthcare Conference on Wednesday, December 4, 2024 at 1:45 pm ET. The live webcast will be available to investors and other interested parties by accessing the Fortrea Investor Relations website. A webcast replay will be available after the event. About Fortrea Fortrea (NASDAQ:FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmac

DURHAM, N.C., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced that Chairman and Chief Executive Officer, Tom Pike and Chief Financial Officer, Jill McConnell will present at the Evercore HealthCONx Conference on Thursday, December 5, 2024 at 10:00 am ET. The live webcast will be available to investors and other interested parties by accessing the Fortrea Investor Relations website. A webcast replay will be available after the event. About FortreaFortrea (NASDAQ:FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutic

For the three months ended September 30, 2024, from continuing operations: Revenues of $674.9 millionGAAP net loss of $(18.5) millionAdjusted EBITDA of $64.2 millionGAAP and adjusted net income (loss) per diluted share of $(0.21) and $0.23, respectivelyBook-to-bill ratio of 1.23x, resulting in 1.15x book-to-bill for the trailing 12 months DURHAM, N.C., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization ("CRO"), today reported financial results for the third quarter ended September 30, 2024. "We had a solid quarter of execution" said Tom Pike, chairman and CEO of Fortrea. "Our book-to-bill ratio for the quarter, as exp

DURHAM, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization ("CRO"), today announced that it will release its third quarter 2024 financial results before the market opens on Friday, November 8, 2024. Fortrea will host a conference call at 8:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings webcast l

For the three months ended June 30, 2024, from continuing operations: Revenues of $662.4 millionGAAP net loss of $(99.3) millionAdjusted EBITDA of $55.2 millionGAAP and adjusted diluted loss per share of $(1.11) and $(0.03), respectivelyBook-to-bill ratio of 0.96x, resulting in 1.16x book-to-bill for the trailing 12 monthsCompleted divestiture of assets relating to the Endpoint Clinical and Patient Access businessesDebt paydown of $504 million in the quarter using initial divestiture and securitization proceedsRevised full-year guidance DURHAM, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contr

DURHAM, N.C., July 17, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Fortrea will host a conference call at 9:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings webcast lin

DURHAM, N.C., July 11, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced that Robert "Bobby" Parks has been appointed as chief accounting officer (CAO), responsible for Fortrea's accounting function, including financial reporting, risk, controls and compliance in accordance with applicable standards, laws and regulations. "We are pleased to welcome Bobby to the Fortrea team, bringing his broad and deep experience from CROs and other fast-paced environments," said Fortrea Chief Financial Officer Jill McConnell. "Bobby has a track record of managing Sarbanes-Oxley Act requirements and internal controls, including for CROs,

DURHAM, N.C., June 27, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced the launch of its artificial intelligence (AI) Innovation Studio, signaling a strategic investment in reshaping the execution of clinical trials today and into the future. The studio will develop and deploy AI and machine learning (ML) technologies to drive speed, agility, quality and enhanced patient safety in the clinical research process by equipping and empowering people to focus on the critical human element of clinical trials. "Patients around the world are waiting for novel, life-changing treatments. With AI, we now have the power—and the ob

DURHAM, N.C., June 19, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced that Chief Financial Officer Jill McConnell will participate in a virtual fireside chat hosted by Elizabeth Anderson, senior managing director at Evercore ISI, to discuss Fortrea's business on Thursday, June 20, 2024 at 2:00 pm ET. Webcast and Replay Information Registration for the live event is required here. The event is scheduled for 30 minutes. A replay will be available by accessing the Fortrea Investor Relations website after the conclusion of the event. About Fortrea Fortrea (NASDAQ:FTRE) is a leading global provider of clinical developme

Citigroup downgraded Fortrea from Buy to Neutral and set a new price target of $23.00 from $30.00 previously

Robert W. Baird downgraded Fortrea from Outperform to Neutral and set a new price target of $25.00 from $28.00 previously

Jefferies downgraded Fortrea from Buy to Hold and set a new price target of $21.00 from $25.00 previously

Evercore ISI downgraded Fortrea from Outperform to In-line and set a new price target of $27.00 from $31.00 previously

Barclays resumed coverage of Fortrea with a rating of Equal Weight and set a new price target of $30.00

Goldman initiated coverage of Fortrea with a rating of Neutral and set a new price target of $28.00

TD Cowen initiated coverage of Fortrea with a rating of Hold and set a new price target of $27.00

Mizuho initiated coverage of Fortrea with a rating of Neutral and set a new price target of $27.00

Robert W. Baird initiated coverage of Fortrea with a rating of Neutral and set a new price target of $43.00

Deutsche Bank initiated coverage of Fortrea with a rating of Hold and set a new price target of $36.00

SAN DIEGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from his position as Executive Chairman of the Board and that the Board of Directors has unanimously elected R. Andrew Eckert to succeed him as Chairman of the Board, effective December 5, 2024. Carl Hull founded Maravai in 2014 and served as Chief Executive Officer, assuming the role of Executive Chairman in October 2022. "Leading Maravai has been the single most rewarding experience in my career. I am extremely proud of what we have

DURHAM, N.C., July 11, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced that Robert "Bobby" Parks has been appointed as chief accounting officer (CAO), responsible for Fortrea's accounting function, including financial reporting, risk, controls and compliance in accordance with applicable standards, laws and regulations. "We are pleased to welcome Bobby to the Fortrea team, bringing his broad and deep experience from CROs and other fast-paced environments," said Fortrea Chief Financial Officer Jill McConnell. "Bobby has a track record of managing Sarbanes-Oxley Act requirements and internal controls, including for CROs,

DURHAM, N.C., May 16, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization ("CRO"), today announced the appointment of Machelle Sanders to the Company's Board of Directors. Ms. Sanders has served as North Carolina's Secretary of Commerce since February 2021 and brings strong domain expertise from more than 30 years of operational and quality assurance roles in pharmaceutical and biotechnology companies. "Machelle's impressive background in life sciences and public service enables her to bring a unique and welcome perspective to our Board," said Tom Pike, chairman and CEO. "She is a highly respected leader, who understands our cu

DURHAM, N.C., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced it convened last week the inaugural meeting of its Site Advisory Board, a collaboration between clinical research investigator sites ("sites") and industry leaders to create a better clinical trial experience for sites, patients and clinical study sponsors ("sponsors") by targeting changes in technology, operational planning and delivery, commercial terms and community engagement. Fortrea places sites and investigators at the forefront of clinical trial planning, leveraging their perspectives to drive changes that will improve the sp

DURHAM, N.C., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced the appointment of John Doyle Dr.P.H., as its new President of Consulting. Doyle will serve on Fortrea's leadership team and lead a team of consultants and advisors with expertise that spans early development through lifecycle management. "Pharmaceutical and biotechnology innovators must constantly navigate complex and fast-changing business and regulatory environments to achieve their mission," said Tom Pike, chairman and chief executive officer of Fortrea. "John has extensive industry knowledge and distinctive technical skills that translate to

144 - Fortrea Holdings Inc. (0001965040) (Subject)

SCHEDULE 13G - Fortrea Holdings Inc. (0001965040) (Subject)

10-Q - Fortrea Holdings Inc. (0001965040) (Filer)

8-K - Fortrea Holdings Inc. (0001965040) (Filer)

8-K/A - Fortrea Holdings Inc. (0001965040) (Filer)

10-Q - Fortrea Holdings Inc. (0001965040) (Filer)

8-K - Fortrea Holdings Inc. (0001965040) (Filer)

8-K - Fortrea Holdings Inc. (0001965040) (Filer)

8-K - Fortrea Holdings Inc. (0001965040) (Filer)

8-K/A - Fortrea Holdings Inc. (0001965040) (Filer)

SC 13G - Fortrea Holdings Inc. (0001965040) (Subject)

SC 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)

SC 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)